[ad_1]
D.R. Horton’s stock slumped in early trading Thursday after the home builder reported fiscal third-quarter earnings that rose above expectations, but the number and value of new home orders were well below forecasts.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...